Dr. Nicholas Hornstein explained the concept of ctDNA and how this blood test may help guide treatment decisions, including whether additional therapy is needed. Dr. William A. Hall sat down with CURE ...

ASCO GU 2022: First-Line Pembrolizumab with or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Study. ASCO GU 2022: Bladder-Sparing ...

ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With ...

- Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking ...

Source: Getty Images ASCO 2025 highlighted groundbreaking and practice-changing studies of immunotherapy, researchers say. Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies ...

Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this episode of Meeting Mic, we bring you pearls and ...

The 2025 ASCO Annual Meeting begins in just nine days, and we look forward to seeing you in Chicago. As you plan your schedule, consider joining the Association for Clinical Oncology’s advocacy events ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations. The 2025 American Society ...

Regional music takes over the Chevron Stadium with a powerful lineup: Virlán García, Alta Consigna, Los Perdidos de Sinaloa, and Los Plebes del Rancho will bring a night of corridos, guitars, and ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical ...